NovaBridge Biosciences (NBP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, NovaBridge Biosciences (NBP) has a cash flow conversion efficiency ratio of 0.007x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($13.15 Million) by net assets ($1.84 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See NovaBridge Biosciences (NBP) liquidity interval to measure how many days the company can operate on defensive assets alone.
NovaBridge Biosciences - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how NovaBridge Biosciences's cash flow conversion efficiency has evolved over time, based on yearly financial data.
NovaBridge Biosciences Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of NovaBridge Biosciences ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Gofore Oyj
HE:GOFORE
|
-0.013x |
|
PChome Online
TWO:8044
|
-0.087x |
|
S-ENJOY SERVICE GR.DL-01
F:78E
|
N/A |
|
Kginicis Co.Ltd
KQ:035600
|
0.020x |
|
Beacon Minerals Limited
AU:BCN
|
0.362x |
|
Tachan Securities Co Ltd
TWO:6020
|
-0.043x |
|
Harvatek Corp
TW:6168
|
-0.006x |
|
Traeger Inc
NYSE:COOK
|
0.102x |
Annual Cash Flow Conversion Efficiency for NovaBridge Biosciences (2017–2024)
The table below shows the annual cash flow conversion efficiency of NovaBridge Biosciences from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see NBP stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $201.16 Million | $-52.65 Million | -0.262x | -517.28% |
| 2023-12-31 | $1.72 Billion | $-72.85 Million | -0.042x | +88.43% |
| 2022-12-31 | $3.01 Billion | $-1.10 Billion | -0.367x | -72.83% |
| 2021-12-31 | $4.59 Billion | $-973.09 Million | -0.212x | -375.29% |
| 2020-12-31 | $5.63 Billion | $433.56 Million | 0.077x | -81.94% |
| 2019-12-31 | $-2.03 Billion | $-867.98 Million | 0.427x | +45.15% |
| 2018-12-31 | $-955.10 Million | $-280.70 Million | 0.294x | -65.06% |
| 2017-12-31 | $-299.80 Million | $-252.16 Million | 0.841x | -- |
About NovaBridge Biosciences
NovaBridge Biosciences, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial fo… Read more